Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Glenmark Pharmaceuticals Limited — Q3 FY25
Glenmark delivered a strong Q3 FY25 with consolidated revenue of INR 3,388 crore, up 35.1% YoY, driven by a 300% surge in India formulation sales to INR 1,064 crore, aided by new launches like Lirafit and Jabryus.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Glenmark delivered a strong Q3 FY25 with consolidated revenue of INR 3,388 crore, up 35.1% YoY, driven by a 300% surge in India formulation sales to INR 1,064 crore, aided by new launches like Lirafit and Jabryus. The US business remained flat at INR 781 crore, but management expects an uptick from FY26 with respiratory ANDA approvals, including Fluticasone MDI and nasal spray, targeting a $600-700 million franchise by FY27. Europe grew 14.8% to INR 730 crore, led by Ryaltris, which is on track to reach $80 million in annual sales. The innovation pipeline, particularly ISB 2001 (trispecific antibody for multiple myeloma), showed promising data with 83% overall response rate, and partnering discussions are underway. Key risks include US FDA inspection delays at the Monroe plant and currency headwinds in emerging markets.
ग्लेनमार्क ने तीसरी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल कमाई 3,388 करोड़ रुपये रही, जो पिछले साल से 35% ज्यादा है। भारत में दवाओं की बिक्री तीन गुना बढ़कर 1,064 करोड़ रुपये हो गई, जिसमें लिराफिट और जैब्रियस जैसी नई दवाओं का हाथ है। अमेरिका में कारोबार स्थिर रहा, लेकिन कंपनी को उम्मीद है कि अगले साल से सांस की दवाओं के मंजूरी मिलने पर बढ़त होगी। यूरोप में 14.8% बढ़त हुई, जिसमें रायल्ट्रिस दवा सालाना 80 करोड़ डॉलर की बिक्री की ओर बढ़ रही है। नई दवा ISB 2001 ने कैंसर के इलाज में 83% सफलता दिखाई है। जोखिमों में अमेरिकी फैक्ट्री की जांच में देरी और विदेशी मुद्रा में उतार-चढ़ाव शामिल हैं।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
US FDA inspection delay at Monroe plant
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
India formulation sales growth
INR 1,064 crore
+300% YoY
India formulation business grew 300% YoY to INR 1,064 crore in Q3 FY25, driven by new launches and strong performance in dermatology and cardiac.
Ryaltris annual sales run-rate
$80 million
+100% YoY (approx)
Ryaltris is on track to achieve $80 million in annual sales, with peak sales potential of $200-300 million as it launches in more markets.
ISB 2001 overall response rate
83%
N/A
ISB 2001, a trispecific antibody for multiple myeloma, showed an 83% overall response rate in Phase 1 data presented at ASH 2024.
US respiratory franchise potential
$600-700 million
N/A
Management guided to a $600-700 million respiratory franchise opportunity from FY27, driven by Fluticasone MDI and nasal spray approvals.
What Changed vs Last Quarter
NEW
India business to achieve 9-10% growth for FY25
Management reiterated guidance of INR 1,100 crore per quarter average, implying 9-10% YoY growth for the full year.
NEW
EBITDA margin improvement of 1-1.5% YoY
Management expects year-on-year EBITDA margin improvement of 1-1.5% going forward, driven by critical launches.
NEW
Fluticasone 44 MDI approval in H1 FY26
The company expects approval for Fluticasone 44 mcg MDI in the first half of FY26, with potential for earlier approval.
NEW
IGI to be self-funded from FY27 onwards
Management expects FY26 to be the last year of Glenmark's capital investment in IGI, with a partnership expected to fund IGI going forward.
DROPPED
Full-year EBITDA margin of ~19%
Management expects FY25 EBITDA margin to be close to 19%, with gradual improvement of 1-1.5% per year thereafter.
DROPPED
Monroe plant resumption by end of FY25
Management expects to reinitiate commercial production at Monroe before end of FY25, following FDA meeting.
DROPPED
First respiratory launch in 6-9 months
Glenmark expects to launch its first respiratory product in the US within 6-9 months, pending approval.
DROPPED
IGI partnership for ISB 2001 by FY26
Management aims to initiate partnering discussions post-ASH 2024 and expects a deal by FY26.
NEW RISK
Currency headwinds in emerging markets
Adverse currency movements in LATAM, South Africa, and Russia impacted reported growth and EBITDA margins by approximately INR 71 crore in Q3.
NEW RISK
India business slowdown in acute respiratory
Q3 India formulation growth was impacted by a slowdown in acute respiratory sales, though management expects recovery in Q4.
NEW RISK
Competition in GLP-1 market
The Indian GLP-1 market is expected to become crowded, potentially limiting Glenmark's market share despite its first-mover advantage with Lirafit.
RISK GONE
US price erosion and competitive pressure
US generic market faces low single-digit price erosion; margins remain under pressure from competition.
RISK GONE
Supply constraints for Lirafit
Lirafit (GLP-1 biosimilar) faced supply issues; resolution expected from December but could impact scaling.
RISK GONE
ROW growth slowdown
ROW revenue declined 4.1% YoY due to high base and geopolitical challenges; full-year growth guided at high single digit.
🤫 Topics management stopped discussing
Mentioned in Q2 FY24, Q4 FY24
EBITDA margin expected to be near 19% for full year FY25, supported by mix improvement and cost control.
Mentioned in Q1 FY24, Q2 FY24
Europe business expected to grow at a minimum of 15-20% going forward, driven by respiratory portfolio and Ryaltris.
Mentioned in Q1 FY25, Q2 FY25
Management expects FY25 EBITDA margin to be close to 19%, with gradual improvement of 1-1.5% per year thereafter.
Mentioned in Q1 FY25, Q2 FY25
Management aims to initiate partnering discussions post-ASH 2024 and expects a deal by FY26.
Mentioned in Q2 FY24, Q4 FY24
Remediation completed but FDA reinspection pending; delay could impact injectable commercialization timeline.
Fast read
Guidance and risk preview
Management reiterated guidance of INR 1,100 crore per quarter average, implying 9-10% YoY growth for the full year.
The Monroe facility is awaiting FDA inspection, delaying potential revenue from injectable products.
View Risks →